Loading organizations...
§ Private Profile · Cambridge, MA, USA
Biotech company developing AI-powered blood tests for early cancer detection and intervention, transforming screening and diagnosis.
Harbinger Health, a private biotechnology company based in Cambridge, MA, pioneers early cancer detection through innovative blood tests. Leveraging artificial intelligence, machine learning, and deep insights into cancer biology, their HarbingerHx platform aims to identify cancer before it becomes visible or symptomatic, enabling crucial early interventions and transforming cancer screening. The company was founded by Flagship Pioneering, which provided an initial commitment of $50 million. Key leadership includes Ajit Singh, appointed CEO in August 2025, and former FDA Commissioner Stephen Hahn, who transitioned to CEO Emeritus. Flagship Founder and CEO Noubar Afeyan also plays a significant role, alongside Co-founder and Board Chair Doug Cole and Chief Innovation Officer Anthony Shuber. Harbinger Health's mission is to revolutionize cancer diagnosis and management, offering a new paradigm for patient care.
Harbinger Health has raised $190.0M across 2 funding rounds.
Harbinger Health has raised $190.0M in total across 2 funding rounds.
Harbinger Health has raised $190.0M in total across 2 funding rounds.
Harbinger Health's investors include Flagship Ventures, Catalyst, Partners Investment, Pictet Alternative Advisors.
Harbinger Health has raised $190.0M across 2 funding rounds. Most recently, it raised $140.0M Series B in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $140M Series B | Flagship Ventures, Catalyst, Partners Investment, Pictet Alternative Advisors | — | Announced |
| Dec 1, 2021 | $50M Series A | Flagship Ventures | — | Announced |
Harbinger Health is a bioplatform company developing blood-based tests for early cancer detection, diagnosis, and management using proprietary biological insights into cancer's origins combined with AI and machine learning.[1][2][3] It targets a multi-cancer screening solution accessible to all, addressing late-stage detection by identifying cancer before symptoms or visibility, enabling proactive interventions.[2][5] The company serves patients, healthcare providers, and systems seeking affordable, high-resolution assays like the HarbingerHx™ platform, with recent data validating its performance across multiple indications.[6] Growth momentum includes a 2021 launch backed by $50 million from Flagship Pioneering, ongoing platform development, and promising clinical data presented at AACR 2025.[3][4][6]
Harbinger Health originated in Flagship Labs in 2018 as a Flagship Pioneering initiative, undergoing three years of research before its official 2021 launch (noted variably as 2020-2021 in sources).[1][2][3][6] Key figures include co-founder and inventor Tony Shuber, a prolific inventor with over 100 patents, including ColoGuard for colorectal cancer screening, and extensive publications in journals like The New England Journal of Medicine.[2] Stephen Hahn, M.D., former FDA Commissioner and MD Anderson Chief Medical Executive, became CEO upon launch, bringing regulatory and clinical expertise.[3][4] Doug Cole, M.D., Flagship Managing Partner, serves as co-founder and Chairman.[3] The idea emerged from discoveries in early cancer biology, aiming to shift from reactive to preemptive care through Bio-AI blood tests.[1][5]
Harbinger stands out in cancer diagnostics through these key strengths:
Harbinger rides the multi-cancer early detection (MCED) trend, fueled by advances in AI, genomics, and liquid biopsies amid rising cancer burdens and demands for proactive health.[2][5][6] Timing aligns with post-COVID emphasis on accessible screening and therapeutic progress outpacing diagnostics, where tools lag in accuracy for early stages.[6] Market forces like aging populations, health equity gaps, and regulatory support for blood tests (e.g., FDA pathways) favor it.[3][4] By pioneering pre-disease signals, Harbinger influences the ecosystem toward preemptive medicine, potentially reducing late-stage burdens on systems and enabling companion therapies, much like Flagship's Model Medicines portfolio.[1][2]
Harbinger is poised to advance its HarbingerHx™ platform toward clinical validation and commercialization, with next steps including expanded trials, regulatory submissions, and multi-cancer product launches.[6] Trends like AI-driven precision oncology and global screening mandates will accelerate adoption, though challenges in specificity scaling and reimbursement loom. Its influence may evolve from pioneer to standard-setter, redefining cancer as a manageable routine via equitable early detection—echoing its founding vision to add years to life by intervening at cancer's origin.[2][5]